HENGRUI PHARMA (01276) announced that as of the disclosure date of this announcement, a total of 2.8303 million shares (accounting for 0.04% of the company's current total share capital) were unlocked in the third lock-up period of its 2022 employee shareholding plan. By November 14, 2025, 1.6568 million shares were non-tradable transfers allocated to the plan's participants, while 1.1735 million shares were sold via centralized bidding. The management committee of the 2022 employee shareholding plan will proceed with the corresponding asset distribution in accordance with the plan's terms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments